2023-506863-32-00CompletedPhase 1
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Sept 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- First submitted
- 11 Jun 2024
- Start date
- 25 Jul 2023
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Multiple sclerosis
- EU CT number
- 2023-506863-32-00
- EudraCT number
- 2022-001209-33
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 5
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fakultni Nemocnice Hradec Kralove | Novy Hradec Kralove | Czechia | Completed |
| KBC Zagreb | Grad Zagreb | Croatia | Completed |
| Klinicki bolnicki centar Sestre milosrdnice | Grad Zagreb | Croatia | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.